Companies›Healthcare›Healthcare›Pharmaceuticals & Biotechnology
NSE:LYKALABS

LYKA LABS LTD.

Healthcare › Pharmaceuticals & Biotechnology
₹77.42
at close · 28 Oct 2026
▼ 1.58 (-2.00%)

Latest filings

Next results: Fri, 30 Oct · Financial Results
  1. Board meeting on Oct 30 to approve Q2 FY26 results · Results
  2. Lyka Labs files Q2 FY27 dematerialisation compliance certificate · Compliance
  3. Trading window closed from Oct 1 ahead of Q2 results · Compliance
All filings ↓
Ask Nexa about LYKA LABS LTD.

Snapshot

What the business is, and whether it's a good one at a fair price.

A Pharmaceuticals & Biotechnology company listed on NSE and BSE, reporting revenue of ₹138 Cr over the trailing twelve months.

Market Cap
₹280 Cr
P / E (TTM)
—
EV / EBITDA
668.4×
Div Yield
—
Growth
8.3%▲
Revenue 5y CAGR
PAT — · EBITDA -77.3%
Quality
3.3%·
ROCE (5y median)
ROE -3.8% (5y median) · margin 0.0%
Leverage
0.53·
Debt / Equity · moderate
Net debt ₹47 Cr
Revenue FY21→FY26
1.5×▲
Margin +5.3 pts
₹86 Cr → ₹128 Cr
Cash conversion
4.69×▲
Operating cash ÷ profit · 5 yrs
₹97 Cr on ₹21 Cr
Moves on a normal day
1.78%·
Median daily move
Last 267 sessions · the yardstick for filing-day moves
Where it sits among 185 Pharmaceuticals peersBar = share of peers beaten · tick = industry median · latest reported figures
P/B#81/163
ROCE#168/183
ROE#158/166
Debt / Equity#140/166
EBITDA margin#111/165
Revenue growth#51/161
Profit growth#36/158

Scorecard

Measured from the filed financials, judged against its Pharmaceuticals peers · as of FY26 — not investment advice

Strengths
Over 5 years it reported ₹21 Cr of profit and ₹97 Cr of operating cash — 4.69×
Profit is converting into cash
Concerns
Returns on capital 3.3% (5-year median)
#168 of 183 in Pharmaceuticals on the latest reported figures · down from 8.4% in FY21
Carries more debt than its peers — 0.53× equity
higher than 84% of its 166 Pharmaceuticals peers
Customers are taking longer to pay — 37 → 100 days of receivables
FY21 → FY26

Charts

How has the market priced it — with filings on the timeline?

LYKALABS · price

Loading chart…

▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.

Peers

How does it stack up on valuation, returns and growth?

Loading peers…

Financials

Quarterly & annual P&L, balance sheet, cash flow, ratios and segments.

Loading financials…

Ownership

Who owns it — and is the promoter stake clean?

Loading shareholding…

Sign up to see the full company file

Governance, sustainability, compliance, earnings calls, presentations, events, reactions and the full filings feed — free with an account.

Common questions

Answered from LYKA LABS LTD.'s filed financials and exchange disclosures

What does LYKA LABS LTD. do?

LYKA LABS LTD. is a Pharmaceuticals & Biotechnology company listed on NSE and BSE, trading under the symbol LYKALABS.

Is LYKA LABS LTD. profitable?

No. Over the trailing twelve months LYKA LABS LTD. reported a net loss of ₹9.39 Cr on revenue of ₹138 Cr.

Does LYKA LABS LTD. pay a dividend?

Not in the latest reported year — LYKA LABS LTD.'s dividend payout for FY26 was nil.

Is LYKA LABS LTD. debt-free?

No. It reported borrowings of ₹48 Cr on its 31 Mar 2026 balance sheet, or net debt of ₹47 Cr after cash. Debt stands at 0.53× equity. That is higher than 84% of its 166 Pharmaceuticals peers.

How much does the LYKA LABS LTD. share price move in a day?

On a typical session LYKA LABS LTD. moves 1.78% — that is the median absolute close-to-close move across its last 267 trading days. MarketPing measures each filing's price reaction against it.

When are LYKA LABS LTD.'s next results?

Financial Results on Fri, 30 Oct. MarketPing alerts you on WhatsApp the moment the filing lands.

Where can I track LYKA LABS LTD.'s announcements?

Every NSE and BSE filing by LYKA LABS LTD. appears on this page, AI-summarised, alongside the price reaction that followed it. Follow the company to get each new filing on WhatsApp within minutes.

Figures are as last reported and may lag the latest filing. Not investment advice.